EUVIMEDEUVIMED entdecken
Fallbericht

Management of a Large Rhabdomyoma with Sirolimus and Antiarrhythmic Agents

Mats Steffi Jennifer Masilamani, Talha Niaz, Philip L Wackel, Justin M Horner, Frank Cetta, Patrick W O'Leary, M Yasir Qureshi

Pediatric Cardiology · 2026

DOI: 10.1007/s00246-025-04030-0 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pediatric Cardiology, 2026. Verfasst von Mats Steffi Jennifer Masilamani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology, Mayo, Clinic Children's, 200 1stSt SW, Rochester, MN, 55905, USA. Hauptthemen laut MEDLINE: Rhabdomyoma, Heart Neoplasms, Sirolimus, Anti-Arrhythmia Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiac rhabdomyomas are the most common pediatric cardiac tumors and are frequently associated with tuberous sclerosis complex (TSC). Large fetal cardiac rhabdomyomas causing inflow or outflow obstruction can lead to hemodynamic compromise and arrhythmias, sometimes necessitating emergent perinatal interventions. We present the fetus of a 32-year-old with multiple intracardiac rhabdomyomas identified at 23 weeks gestation. The largest, located in the left atrium (LA), enlarged by 32 weeks, causing mitral inflow obstruction and moderate mitral regurgitation (MR). Maternal sirolimus therapy was initiated, leading to tumor regression and permitting delivery at 39 weeks without the need for fetal or neonatal surgery. Postnatally, the infant developed hemodynamically significant refractory arrhythmias, requiring antiarrhythmics and inotropic support. Continued sirolimus therapy further reduced tumor burden and improved MR. This case adds to the growing evidence supporting transplacental sirolimus therapy (mTOR inhibition) for managing large, hemodynamically significant fetal cardiac rhabdomyomas. It also underscores the importance of anticipating and aggressively managing associated arrhythmias.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhabdomyomaHeart NeoplasmsSirolimusAnti-Arrhythmia AgentsFetal DiseasesHumansFemaleAdultPregnancyInfant, NewbornUltrasonography, Prenatal

Stichwörter der Autor:innen

ArrhythmiaRhabdomyomaSirolimusTransplacental

Substanzen

SirolimusAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology, Mayo, Clinic Children's, 200 1stSt SW, Rochester, MN, 55905, USA.
  • Department of Pediatric Cardiology, Sanford Health, 737 Broadway N, Fargo, ND, 58102, USA.
  • Department of Pediatrics, Comer Children's Hospital, The University of Chicago, 5721 S Maryland Ave, Chicago, IL, 60637, USA.
  • Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology, Mayo, Clinic Children's, 200 1stSt SW, Rochester, MN, 55905, USA. qureshi.muhammad@mayo.edu.

Zitieren

APA

Masilamani, M. S. J., Niaz, T., Wackel, P. L., Horner, J. M., Cetta, F., O'Leary, P. W., & Qureshi, M. Y. (2026). Management of a Large Rhabdomyoma with Sirolimus and Antiarrhythmic Agents. Pediatric Cardiology. https://doi.org/10.1007/s00246-025-04030-0

Vancouver

Masilamani MSJ, Niaz T, Wackel PL, Horner JM, Cetta F, O'Leary PW, et al. Management of a Large Rhabdomyoma with Sirolimus and Antiarrhythmic Agents. Pediatric Cardiology. 2026. doi:10.1007/s00246-025-04030-0

BibTeX
@article{Masilamani2026,
  author = {Masilamani, Mats Steffi Jennifer and Niaz, Talha and Wackel, Philip L and Horner, Justin M and Cetta, Frank and O'Leary, Patrick W and Qureshi, M Yasir},
  title = {Management of a Large Rhabdomyoma with Sirolimus and Antiarrhythmic Agents},
  journal = {Pediatric Cardiology},
  year = {2026},
  doi = {10.1007/s00246-025-04030-0}
}
Kostenlos starten →